A Study of Solanezumab (LY2062430) in Participants With Prodromal Alzheimer's Disease
Status:
Terminated
Trial end date:
2017-05-01
Target enrollment:
Participant gender:
Summary
The main purpose of this study is to investigate the safety and efficacy of the study drug
solanezumab in participants with prodromal Alzheimer's disease (AD).